Medicaid reimbursements are shrinking, providers are pulling back, and vulnerable populations are losing access to care. Akido Labs is betting that AI can expand care capacity fast enough to reverse that trend.

This week, Halle sits down with Prashant Samant, co-founder and CEO of Akido Labs, to discuss what it actually takes to scale care with AI. They explore why Akido built a full-stack healthcare company, how its AI operates inside real clinical workflows, and why the hardest patients are the best place to test whether this model works.

We cover:

• Why he chose to build a full-stack care model
• How AI changes who can deliver care, and where
• Why most healthcare AI tools fail once they hit real clinical workflows
• Why the doctor shortage cannot be solved by training more doctors
• How the bottleneck in healthcare AI is absorption, not innovation

About our guest:

Prashant S. Samant is CEO and co-founder of Akido, a healthcare technology company that builds clinical AI and operates a multi-state medical network serving hundreds of thousands of patients. He co-founded Akido in 2015 through USC’s Digital Health Lab. In 2023, he and his co-founders received the EY Entrepreneur of the Year–Greater Los Angeles Award. Samant is also a co-founder and board member of Grid110, a nonprofit accelerator supporting early-stage entrepreneurs. He holds a bachelor’s degree in economics from Washington University in St. Louis.

— 

Show Notes:

• Akido’s recently-published white paper on street medicine

— 

🙏 Do you like this podcast? An easy and free way to help keep the show going is to leave us a review on Apple, Spotify, or wherever you're listening.

— 

📍 Connect with us:

Heart of Healthcare website

LinkedIn

YouTube 

See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

AI is everywhere in healthcare, and May's big question is whether it's actually delivering. The money is flowing, the promises are bold, but some cracks are starting to show.

Steve and Michael break down the month's biggest stories.

We cover:

• Digital health hitting its strongest funding quarter since the pandemic peak, and why deal concentration tells the real story
• How Medvi built a billion-dollar GLP-1 company on fake doctor profiles, fake reviews, and a drug with zero bioavailability
• Why AI in prior authorization and billing may be inflating healthcare costs rather than cutting them
• The peptide craze: what the science says, what regulators have banned, and why Michael is actually taking one
• How AI could collapse today's narrow medical specialties into a "generalist specialist" model
• New research showing Epic's out-of-the-box AI models fall short on real-world clinical benchmarks

—

Show notes:

Rock Health Q1 2026 Funding Report

NYT Profile of Medvi + Futurism Investigation

Peterson Health Technology Institute: Administrative AI Report

STAT News / Undark: BPC-157 and the Peptide Craze

Health Affairs Scholar: Kocher & Wachter on the Generalist-Specialist Model

Springer Nature / Journal of General Internal Medicine: Epic AI Model Meta-Analysis

— 

🙏 Do you like this podcast? An easy and free way to help keep the show going is to leave us a review on Apple, Spotify, or wherever you're listening.

— 

📍 Connect with us:

Heart of Healthcare website

LinkedIn

YouTube 

See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Forty million people use ChatGPT for health-related questions every day, making it one of the most widely used tools for health information in the world. So what is their team doing to maximize impact and minimize harm? For one, they've brought in hundreds of physicians globally to continuously review outputs and shape how the models respond across different scenarios, literacy levels, and edge cases. Second, they've hired my Rock Health co-founder, Nate Gross, MD, as their VP of Health.

In this full-circle episode, I sit down with Nate, who also co-founded Doximity (DOCS) and knows a thing or two about building in digital health. We discuss the astonishing speed of AI progress, how models are trained for safety and accuracy, and what this technological evolution means for every part of the healthcare system.

Key topics:

• How ChatGPT is becoming a 24/7 front door for health questions, and whether it is replacing Dr. Google or starting to compete with the healthcare system itself
• How OpenAI is trying to reduce hallucinations, avoid sycophantic behavior, and build guardrails for sensitive use cases like mental health
• OpenAI’s goals to “raise the floor, sweep the floor, and raise the ceiling” with new product launches like ChatGPT for Clinicians and GPT-Rosalind
• How Nate thinks about the AI race and what winning in healthcare actually requires
• Where startups should focus their efforts now that specialized products are launching for clinicians and life sciences
• The single hardest problem in healthcare that AI, according to Nate, probably won't fix anytime soon

— 

About our guest:

Dr. Nate Gross is the VP of Health at OpenAI. He previously co-founded Doximity and Rock Health. He graduated from the Emory University School of Medicine with an MD, Harvard Business School with an MBA, and Claremont McKenna College with a BA in Government. He serves as affiliated faculty for the Clinical Informatics Fellowship at Stanford.

— 

Show notes:

• ChatGPT for Clinicians
• ChatGPT for Health (for patients)
• OpenAI for Healthcare
• GPT-Rosalind

— 

🏆 Thank you for your votes! We're excited to share that the Heart of Healthcare is a Webby Award Winner for 2026!

— 

📍 Connect with us:

Heart of Healthcare website

LinkedIn

YouTube 

See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Nearly one billion prescriptions are abandoned at the pharmacy counter every year, often because patients are blindsided by the cost.

This week, co-host Halle Tecco is joined by Wendy Barnes, President and CEO of GoodRx, to discuss the chaos of prescription drug pricing, the murky world of Pharmacy Benefit Managers (PBMs), and how digital tools are changing patient affordability. They break down the layered system of manufacturers, payers, and pharmacies that creates inconsistent pricing, and explore the current push for greater transparency.

We cover:

• The cascade of drug pricing: from initial manufacturer costs and rebates to payer and pharmacy contracts, which results in vast price variability for consumers
• What it would take to get to price transparency in drug pricing
• The current pressures on PBMs, including efforts to ban "spread" and the practice of offshoring rebate contracting for tax advantages
• Why pharmacies haven’t gone online like other areas of consumer goods
• The future of medication access, including the growth of pharma’s direct-to-patient programs and the low current adoption of home delivery despite widespread retail pharmacy closures

— 

About our guest:

Wendy Barnes is the President and CEO of GoodRx. She has over 30 years of leadership experience across the pharmacy and medical benefit industry. Most recently, Wendy served as CEO of RxBenefits, where she led the company in providing pharmacy benefit support to more than 2,000 self-insured clients, representing over 3 million lives. Prior to that, she served as President of Express Scripts Pharmacy, overseeing operations for 100 million beneficiaries. Her leadership spans roles at Rite Aid, Premier Inc., and the U.S. Air Force, where she served as a Medical Service Corps Officer. She holds a B.S. degree in Biochemistry from the United States Air Force Academy and an M.B.A. degree from the University of Alaska Anchorage.

— 

📍 Connect with us:

Heart of Healthcare website

LinkedIn

Youtube 

See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Pete McCanna, CEO of Baylor Scott & White Health, believes that health systems are built around the wrong objective… and he has an ambitious goal to change that.

This week, Halle sits down with McCanna to unpack how one of the largest and most successful health systems in the country is shifting from a supply-driven model to one built entirely around the customer. They discuss why legacy systems operate like “walled castles,” what it takes to redesign care around real conditions instead of departments, and how Baylor Scott & White is testing a model that prioritizes access, personalization, and long-term trust over short-term profit.

We cover:

• Why most health systems are structured to fill capacity, not create value for patients
• The reason why he uses the term "customer" instead of "patient" (and how his colleagues initially responded)
• How loyalty and trust make it economically sound to offer services that lose money.
• The strategy for deploying AI to create product differentiation for patients rather than just improving internal efficiency
• The limits of the “payvider” model and why it’s harder than it looks
• The three healthcare laws he thinks need to be rewritten

—

About our guest:

As CEO of Baylor Scott & White Health, Peter (Pete) McCanna is focused on empowering customers to live well by reimagining traditional healthcare—offering more convenient, personalized, and informed experiences. He is leading Baylor Scott & White’s customer-centric transformation by bringing together the system’s 59,000 team members around a common goal to keep people healthy and feeling connected and supported.

Before becoming CEO, Pete served as the health system’s president. In that role, he drove operational excellence, strengthened clinical alignment, scaled the system’s digital health platform, MyBSWHealth, and deepened academic partnerships to address the critical need for healthcare professionals.

Pete has nearly 40 years of industry experience. As executive vice president and chief operating officer at Northwestern Medicine, he exceeded targets for operating revenue, quality, patient experience, and employee engagement, making it one of the top 10 academic health centers in the country.

Known as a thoughtful and innovative leader, Pete formerly served as chief financial officer at New Mexico-based Presbyterian Healthcare Services and the University of Colorado Hospital.

Passionate about transforming healthcare, Pete was named one of Modern Healthcare’s “100 Most Influential People in Healthcare.” Driven by a deep sense of purpose, Pete currently serves as the inaugural board chair of Longitude Health, an innovative healthcare collaborative, and as a board member of University of Michigan Health, Texas Hospital Association, and Catholic Extension. He holds a master’s degree in Public Affairs at the University of Texas at Austin and a bachelor’s degree in English from the University of Michigan.

Baylor Scott & White Health is the largest not-for-profit health system in the state of Texas. It includes 55 hospitals, more than 1,300 access points, a health plan, a research institute, and an accountable care organization, plus Levanto—a company offering digitally-enabled health solutions—and 3.5 million customers connected through MyBSWHealth.

—

Snow notes:

• Visit BSWHealth.com to learn more.
• Download the MyBSWHealth app.
• Explore Levanto.Health to learn about employer solutions built on Baylor Scott & White's digital platform and care model.

—

📍 Connect with us:

Heart of Healthcare website

LinkedIn

Youtube 

See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

We’re back with our monthly rundown of the top headlines in health tech!

Today, Halle flies solo to share the biggest stories that shaped Q1, from the rising pressures on PBMs to how consumers are using AI.

Stories covered:

• What's happening to PBMs (it's not pretty)
• New data from Rock Health on consumer use of AI
• Social media companies find liable for addictive design
• Healthcare hiring is slowing as efficiency becomes the focus
• Have we finally bent the healthcare cost curve in the United States?

—

The Heart of Healthcare podcast was nominated for a Webby award! We'd so appreciate if you could create a quick account and vote for us here.

—

📍 Connect with us:

Heart of Healthcare website

LinkedIn

Instagram

Youtube

See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Last year, his independent pharmacy spent $13 million on brand-name drugs for patients processed by the three biggest Pharmacy Benefit Managers (PBMs) which earned a profit margin of 0.01%.

In this episode, Halle speaks with Alec Ginsberg, owner and fourth-generation pharmacist at C.O. Bigelow, the oldest surviving apothecary–pharmacy in the United States. Alec is fighting against the forces squeezing independent pharmacies and charting a course for the future of the pharmacist.

We cover:

• How the roll-up of PBMs, health plans, and retail pharmacies changed everything
• What led him to remove his pharmacy’s Rx-filling robot
• The dramatic decline of independent pharmacies along with the closures of big box pharmacy stores
• The one health policy he would put in place today to save independent pharmacies
• The history of the pharmacist's role and what’s next
• What he really thinks about compounding pharmacies and the Hims vs. Novo lawsuit

—

About our guest: 

Alec Wade Ginsberg is the fourth-generation pharmacist, owner, and Chief Operating Officer of C.O. Bigelow Apothecary, America’s oldest pharmacy, founded in 1838 and still operating in New York City’s West Village. With a Doctor of Pharmacy degree from the University of North Carolina Eshelman School of Pharmacy, Alec bridges the clinical world of pharmacy with the realities of modern consumer culture.

At Bigelow, he oversees the brick-and-mortar beauty retail and pharmacy operations, navigating everything from prescription drug shortages to the pressures of today’s PBM-dominated marketplace. Beyond the counter, Alec is the founder and writer of Drugstore Cowboy, a weekly newsletter that dissects the intersection of drugs, business, and consumer culture — making the hidden mechanics of the U.S. healthcare system both understandable and entertaining for thousands of readers.

His work has been featured across national media, and he’s become a trusted voice for translating complex pharmaceutical issues — from GLP-1s to compounding to drug pricing — into plain English. Alec’s mission is simple: to make Americans smarter about the pills in their cabinets and the system that puts them there.

—

Show notes:

• Drugstore Cowboy - Alec’s free and super interesting newsletter
• C.O. Bigelow - The Nation’s Oldest Apothecary
• Virtual GLP-1 startups: Pill mills or the future of obesity care?

—

📍 Connect with us:

Heart of Healthcare website

LinkedIn

Instagram

Youtube

See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Chris Klomp, Director of Medicare and Deputy Administrator of CMS, and Senior Advisor to HHS Secretary RFK Jr., has big ambitions to reshape how healthcare works in the United States.

This week, ​​Steve sits down with Klomp to discuss how his experience as a digital health entrepreneur is guiding his current role overseeing a roughly $2 trillion department. Klomp shares the government's strategy for restoring trust between providers and payers, driving down costs, and addressing a system where approximately 90% of healthcare dollars are still spent in a fee-for-service arrangement. 

We cover:

• Why 90% of US healthcare remains fee-for-service after two decades of reform.
• The intentional design of the new Access model to be deflationary and fuel entrepreneurship among insurgents.
• The commitment from the payer industry to make prior authorization invisible to patients and providers by 2027.
• CMS's aggressive stance on data interoperability and funding enforcement against data blocking.
• How the Most Favored Nation policy is re-wiring global prescription drug supply to lower prices without compromising innovation.

—

About our guest: 

Chris Klomp is the Director of Medicare and Deputy Administrator of CMS, and Senior Advisor to HHS Secretary Robert F. Kennedy Jr. With extensive experience in healthcare payment reform and data sharing, he built and led Collective Medical, the largest U.S. real-time care collaboration data network, acquired by PointClickCare in 2020. There, he partnered with health systems, plans, providers, post-acutes, and state governments to advance value-based care through enhanced data access and insights.

Chris has driven healthcare reform at state and federal levels, focusing on value-based care and interoperable health technology. Through Endurance Companies, a San Francisco-based multi-family office he co-founded with Stanford classmates, he has co-founded, invested in, advised, and served on the board of many innovative healthcare organizations, including Nomi Health, Maven Clinic, InnovaCare Health, and Health Joy. He also served as a Utah Senate-confirmed commissioner of the Utah Digital Health Services Commission, where he focused on leveraging technology for cost-effective, healthier outcomes. Previously, he was Vice President in Bain Capital’s North American Private Equity group and worked at Bain & Company. Recognized as Utah Business’ CEO of the Year and EY’s Mountain Region Entrepreneur of the Year, Chris holds a B.A. with honors in Economics and English from Brigham Young University and an MBA from Stanford.

—

🙏 Thank you to our show sponsor, Quickstudy PR, story brokers for leading healthcare executives. Learn more about quickstudypr.com.

—

📍 Connect with us:

Heart of Healthcare website

LinkedIn

Instagram

Youtube 

See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

This week, Halle and Michael sit down for a special in-person listener Q&A to answer a range of founder questions you submitted.

Topics include:

• What investors are prioritizing right now and how first-time founders can stand out
• How to think about board seats
• What to do if your growth has plateaued
• Things to keep in mind when negotiating a health system contract
• How to think about choosing between small funds and mega-VCs
• What “pay to play” really means
• How to handle co-founder equity when someone leaves early

—

📍 Connect with us:

Heart of Healthcare website

LinkedIn

Instagram

Youtube 

See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Breakthrough blood tests that can flag dozens of cancers before symptoms appear are gaining momentum, yet questions remain about accuracy, equity, and how these tools will fit into routine care.

In this episode, Steve talks with Helmy Eltoukhy, co-founder and co-CEO of Guardant Health, a $14 billion publicly-traded precision oncology company. The conversation explores the science behind cell-free DNA, the rise of blood-based cancer screening, and the broader shift toward data-driven diagnostics.

We cover:

• How liquid biopsy works and why cell-free DNA became such a powerful tool
• The path from late-stage applications to large-scale early detection
• What Medicare coverage of blood-based colorectal cancer screening signals for adoption
• The operational and regulatory hurdles that shape diagnostics businesses
• Lessons from Helmy’s entrepreneurial path across sequencing, diagnostics, and company-building

—

About our guest: 

Helmy Eltoukhy is the chairman and co-CEO of Guardant Health, a leading precision oncology company he co-founded in 2012. He is also an active investor and is involved in over 30 startup companies across the technology and healthcare sectors. In December 2024, Eltoukhy expanded his ventures into sports ownership by co-leading the acquisition of Sheffield United Football Club through COH Sports of which he is currently co-chairman.

Last year, he was named by TIME100 Health as one of the most influential people in global health. He was also on Time Magazine’s inaugural list of the 50 Most Influential People in Health Care and has been recognized by Fortune (40 under 40), the World Economic Forum (Technology Pioneer), and on the list of the Top 50 Healthcare CEOs in 2021.

Beyond his entrepreneurial endeavors, Eltoukhy is deeply committed to various philanthropic efforts and serves on the boards of the Prostate Cancer Foundation, the SETI Institute (Search for Extraterrestrial Intelligence), and the UCSF Cancer Leadership Council. Prior to founding Guardant Health, Eltoukhy co-founded Avantome in 2007 to commercialize semiconductor sequencing, which was later acquired by Illumina. Eltoukhy is a named inventor on over 100 patents and holds PhD, MS, and BS degrees in electrical engineering from Stanford University.

—

Learn more about the Rock Health CEO Summit at the New York Stock Exchange on March 27th.

—

📍 Connect with us:

Heart of Healthcare website

LinkedIn

Instagram

Youtube 

See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Pharma ads, biotech IPOs, $1M longevity programs, oh my!

This month's Digital Health Download skews towards biotech, which is having a moment. Tune in to hear Halle and Michael cover the latest headlines.

We cover:

• Why pharma ads are surging and the growing push for restrictions on D2C drug advertising
• Hims & Hers’ $1.15B acquisition of Eucalyptus, its global expansion strategy, and the FDA crackdown on compounded GLP‑1 drugs
• The return of biotech IPOs, with Eikon Therapeutics and Generate Biomedicines signaling investor interest in platform‑based drug discovery
• Vaccine makers scaling back research amid policy uncertainty, declining uptake, and tighter funding
• TrumpRx’s “most favored nation” drug pricing approach, and what one STAT analysis found
• Bryan Johnson’s $1M per year “Immortals” longevity program

—

Show notes:

• Should drug companies be advertising to consumers? (The New York Times) 
• Hims & Hers Enters $1.15 Billion Agreement to Acquire Eucalyptus (PharmExec.com)
• A sign biotech is back? Four drugmakers go public, raising nearly $1 billion in all (STAT)
• Vaccine Makers Curtail Research and Cut Jobs (The New York Times) 
• TrumpRx claims to offer the lowest prices. But many drugs have cheaper generics (STAT)
• Bryan Johnson's Immortals: $1M to try longevity regimen (Axios) 

—

"Halle Tecco wanted to see tech used for better medical services and getting people engaged in their own health. Now, she’s written a book on how she went about it." - The WSJ

Massively Better Healthcare is out now!

—

Rock Health's annual CEO Summit is returning to the New York Stock Exchange on March 27th! Learn more and nominate a CEO to join this invite-only event here.

—

📍 Connect with us:

Heart of Healthcare website

LinkedIn

Instagram

Youtube

See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.